Trial Profile
A Randomized, Single-Blind, Four-Period Crossover Study Examining the Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet Dosing (NN4440) in Fasting and Fed Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Feb 2017
Price :
$35
*
At a glance
- Drugs Repaglinide/metformin (Primary) ; Metformin; Repaglinide
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 09 Dec 2011 Official Title amended as reported by ClinicalTrials.gov.
- 09 Dec 2011 Primary endpoints identified as reported by ClinicalTrials.gov.
- 09 Dec 2011 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.